TP53 and neuroblastoma: Based on this, it appears possible that the careful design of therapeutic strategies and administration schedules aimed at attacking cancer cells on distinct, biologically relevant pathways, such as DDR and ARF/MDM2/p53 circuitry, might be highly effective and at the same time able to circumvent development of biological resistances in order to significantly contribute to defeat MNA neuroblastoma tumors.